Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-HVEM Antibody (5V101) is a Mouse antibody targeting HVEM. Anti-HVEM Antibody (5V101) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $199 | 7-10 days |
Description | Anti-HVEM Antibody (5V101) is a Mouse antibody targeting HVEM. Anti-HVEM Antibody (5V101) can be used in ELISA. |
Alias | tumor necrosis factor receptor superfamily, member 14, TR2, LIGHTR, HVEM, HVEA, CD270, ATAR |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 5V101 |
Reactivity | Human |
Application | ELISA |
Recommended Dose | ELISA: 1:1000-1:2000 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human HVEM/TNFRSF14/CD270 (rh HVEM/TNFRSF14/CD270; TMPY-01750; NP_003811.2; Met1-Val202). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Herpesvirus entry mediator (HVEM), also referred to as TNFRSF14, TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a member of type I transmembrane protein belonging to the TNF-receptor superfamily. It is expressed on many immune cells, including T and B cells, NK cells, monocytes, and neutrophils. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling. However, recent studies have revealed that HVEM is also involved in the unique inhibitory signaling pathway for T cells through activating tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) in B and T lymphocyte attenuator (BTLA). HVEM provides a stimulatory signal following engagement with LIGHT (TNFSF14) on T cells. In contrast, it can also provide an inhibitory signal to T cells when it binds the B and T lymphocyte attenuator (BTLA), a ligand member of the Immunoglobulin (Ig) superfamily. Thus, HVEM may be viewed as a molecular switch, capable of facilitating both stimulatory and inhibitory cosignaling in T cells. Substantial evidence from both human disease and from experimental mouse models has indicated that dysregulation of the LIGHT-HVEM-BTLA cosignaling pathway can cause inflammation in the lung and in mucosal tissues.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Immunogen | Recombinant Human HVEM/TNFRSF14/CD270 Protein (TMPY-01750) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.